Core Viewpoint - The recent IPOs of Huazhang Biotechnology and Hansai Aitai have faced significant market backlash, with both companies experiencing substantial stock price declines on their first trading days, indicating a potential shift in investor sentiment towards biotech firms, particularly those classified as "unprofitable 18A" [1][3][9]. Group 1: IPO Performance - Huazhang Biotechnology's stock fell nearly 30% on its debut, while Hansai Aitai's stock opened at 28.9 HKD, down 9.69% from its issue price of 32 HKD, and closed at 17.20 HKD, marking a 46.25% drop [1][3]. - Hansai Aitai's IPO was characterized by a high subscription rate of 3074.09 times for the public offering, with only 10% of shares allocated to this segment, reflecting strong initial interest despite the subsequent price drop [3][4]. Group 2: Company Background and Strategy - Hansai Aitai is a biotech company focused on innovative therapies for cancer and autoimmune diseases, utilizing its proprietary VersatiBody platform to develop dual-function or multi-functional molecules [10]. - The company has a rich pipeline, including its lead product HX009, a PD-1/SIRPα dual-function antibody fusion protein, which is currently in various clinical trials [11]. Group 3: Financial Metrics and Valuation - The IPO pricing was set at the upper limit of 32 HKD, raising approximately 5.31 billion HKD, but the post-IPO market valuation of 23.43 billion HKD corresponds to a high price-to-book ratio of 21.77, significantly above the industry average of 4.81 [4][13]. - Financial losses for Hansai Aitai were reported at 85.16 million HKD, 117 million HKD, and 87.43 million HKD for the years 2023, 2024, and the first eight months of 2025, respectively, raising concerns about its valuation amidst ongoing losses [12].

Group 1 - The core viewpoint of the article is that Hansai Aitai Biopharmaceutical Technology (Wuhan) Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, with ICBC International as the exclusive sponsor [1] - The company focuses on structural biology, translational medicine, and clinical development, having developed an innovative drug pipeline since 2016, including its core product HX009 and nine other pipeline candidates [1][2] - HX009 is a self-developed PD-1/SIRPα dual-function antibody fusion protein currently undergoing multiple clinical trials in China for treating advanced melanoma, relapsed/refractory EBV-positive non-Hodgkin lymphoma, and advanced biliary cancer [1][2] Group 2 - The company has two main products, HX301 and HX044, with HX301 being a multi-target kinase inhibitor in a Phase II clinical trial for glioblastoma in China, and HX044 being a novel dual-function anti-CTLA-4 antibody SIRPα fusion protein in Phase I/IIa trials for advanced solid tumors in Australia and China [2] - According to a Frost & Sullivan report, HX009 is leading globally in clinical trial progress among similar CD47-targeting bispecific antibodies/dual-function fusion proteins, while HX044 is the only CTLA-4/SIRPα dual-specific antibody/dual-function fusion protein in clinical trials [2] - The company has developed proprietary platforms, VersatiBody and autoRx40, for creating antibody drugs with enhanced therapeutic capabilities, and has received royalties from HX008, a PD-1 monoclonal antibody approved in 2022 [2] Group 3 - As of the fiscal years ending December 31, 2023, and 2024, the company's R&D costs are projected to be RMB 46.7 million and RMB 74.7 million, accounting for 73.0% and 61.8% of total operating expenses, respectively [2] - The company has not yet achieved profitability and continues to invest heavily in R&D activities [2] - The company faces significant risks, including uncertainties in drug development, potential unmet expectations in clinical trial results, and challenges in obtaining regulatory approvals or commercializing its products [3]